Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonate Clear all

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
Interventions: bortezomib; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ischemic Cardiomyopathy, Dilated Cardiomyopathy, Inflammation, Sudden Cardiac Death
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rett Syndrome, Prader-Willi Syndrome, Angelman Syndrome, Sleep Problems
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 18 Years
Enrollment: 804 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Birmingham, Alabama • Irvine, California • San Diego, California + 6 more

Conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Interventions: cytotoxic t-lymphocytes; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Month to 79 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more

Conditions: Hypoxic Ischemic Encephalopathy
Interventions: blood sample; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 1 Day to 3 Days
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 30 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sepsis, Congenital Diaphragmatic Hernia, Neonatal Cardiopulmonary Failure
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 2 Months
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Photo therapy; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Primary Immune Deficiency
Interventions: Newnorm; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Irvine, California • Centennial, Colorado • Port Saint Lucie, Florida + 7 more

Conditions: Atopic Dermatitis
Interventions: Cetaphil Restoraderm, Standard of Care; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Day to 3 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Fanconi Anemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: biologic sample preservation procedure, biopsy; Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome, Early Infantile Epileptic Encephalopathy, FOXG1 Syndrome, KBG Syndrome, Noonan Syndrome, Severe Hemophilia A, Short Bowel Syndrome, Beta-Propeller Protein-Associated Neurodegeneration, Brain Injury of Prematurity With Periventricular Leukomalacia, Chromosome 17p13.3 Microdeletion Syndrome, Chromosome 1q43-1q44 Deletion, Cockayne Syndrome, Congenital Diaphragmatic Hernia, End-Stage Renal Disease With Cloacal Anomaly, Mitochondrial Depletion Disorder, Severe Factor VII Deficiency
Interventions: Family Centered pediatric palliative care for family caregivers of children with rare diseases.; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 12 Months to 99 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Fanconi Anemia
Interventions: Eltrombopag; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 6 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Premature Birth, Premature Infant, Premature, Intrauterine Growth Restriction, Small for Gestational Age at Delivery
Interventions: PEAPOD Infant Body Composition measuring device; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 22 Weeks to 32 Weeks
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sickle Cell Anemia
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 10 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 11
States / cities: Aurora, Colorado • Atlanta, Georgia • Peoria, Illinois + 7 more

Conditions: Neurofibromas, Cutaneous, Neurofibromatosis 1
Interventions: Kybella; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Shwachman-Diamond Syndrome, SDS, IBMF, Congenital Neutropenia, Heme Malignancy, Shwachman Syndrome, Inherited Bone Marrow Failure, Exocrine Pancreatic Insufficiency, WHIM, ELANE, SBDS Gene Mutation, EFL1 Gene Mutation, DNAJC21 Gene Mutation, SRP54 Gene Mutation, Inherited Cancer Syndrome, Inherited Cancer-Predisposing Syndrome, Neutropenia, Severe Chronic, Neutropenia Other, Neutropenia Chronic Benign, Ribosome Alteration, Ribosomopathy, Immune Deficiency, Inherited BMF Syndrome, Inherited Immunodeficiency Diseases, Cognitive Delay, Mild, Myelodysplastic Syndromes, Pancytopenia
Interventions: Not listed
Lead sponsor: Shwachman-Diamond Syndrome Alliance Inc; Other
Eligibility: Not listed
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2088
U.S. locations: 1
States / cities: Woburn, Massachusetts

Conditions: Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
Interventions: Norovirus -specific T-cell (NST) therapy; Biological
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Months to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: GMI-1070; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Oakland, California • Sacramento, California • Durham, North Carolina

Conditions: Rett Syndrome
Interventions: Dextromethorphan; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 2 Years to 15 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab; Dietary Supplement · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more

Conditions: Dilated Cardiomyopathy, Primary Prevention of Sudden Cardiac Death, Implantable Cardioverter Defibrillator
Interventions: Not listed
Lead sponsor: Catholic University of the Sacred Heart; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death

Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)

Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis

Inflammatory Cytokine Quantification in Infants

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

Tissue Sample Collection From Patients With Fanconi Anemia

Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients

Palliative Care Needs of Children With Rare Diseases and Their Families

Eltrombopag for Fanconi Anemia

Growing Little PEAPODS Study

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Trial of Dextromethorphan in Rett Syndrome

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Electrophysiologic and Morphologic Assessment of the Substrate to Guide Implantation of Defibrillators in Dilated Cardiomyopathy